

Draft
Therapeutic Classes For Review At the October/November 2016
Pharmaceutical & Therapeutics Committee Meeting
(List provided by Nina Bandali, Magellan Medicaid Administration/Provider
Synergies, 4/21/2016)

Therapeutic Class

ALZHEIMER'S AGENTS

ANTI-ALLERGENS, ORAL - New

ANTIDEPRESSANTS, OTHER

ANTIDEPRESSANTS, SSRI_s

ANTIHISTAMINES, MINIMALLY SEDATING

ANTIHYPERTENSIVES, SYMPATHOLYTIC

ANTIHYPURICEMICS, ORAL

ANTIPARKINSON'S AGENTS

ANTIPSORIATICS, ORAL

ANTIPSORIATICS, TOPICAL

ANTIPSYCHOTICS

BILE SALTS

BOTULINUM TOXINS - New

BRONCHODILATORS, BETA AGONIST

COLONY STIMULATING FACTORS - New

COPD AGENTS

CYTOKINE AND CAM ANTAGONISTS

EMOLLIENTS

EPINEPHRINE, SELF INJECTED - New

ERYTHROPOIESIS STIMULATING PROTEINS

GI MOTILITY CHRONIC - New

GLUCOCORTICOID, INHALED

HISTAMINE II RECEPTOR BLOCKERS

IDIOPATHIC PULMONARY FIBROSIS - New

IMMUNOMODULATORS FOR ATOPIC DERMATITIS

IMMUNOMODULATORS, TOPICAL

INTRANASAL RHINITIS AGENTS

LEUKOTRIENE MODIFIERS

MACULAR DEGENERATION AGENTS - New

NEUROPATHIC PAIN

NSAIDS

OPHTHALMIC ANTIBIOTIC/STEROID COMBINATIONS

OPHTHALMIC ANTIBIOTICS

OPHTHALMIC ANTI-INFLAMMATORIES

OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS

OPHTHALMICS, GLAUCOMA AGENTS

OTIC ANTIBIOTICS

OTIC ANTI-INFECTIVES & ANESTHETICS

PROGESTATIONAL AGENTS (MAKENA ONLY) - New

SEDATIVE HYPNOTICS

SMOKING CESSATION

STEROIDS, TOPICAL

STIMULANTS AND RELATED AGENTS

gbm/PBM/4.27.2016

DRAFT